Prognostic Relevance of Clinical Risk Factors in Mantle Cell Lymphoma

Seminars in Hematology

Volumn 48, Issue 3, 2011, Pages 185-188

  Hoster, Eva ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LACTATE DEHYDROGENASE;

AGE; ARTICLE; EUROPE; HUMAN; LEUKOCYTE COUNT; MANTLE CELL LYMPHOMA; MCL INTERNATIONAL PROGNOSTIC INDEX; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PERFORMANCE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; SURVIVAL; VALIDATION STUDY;

HUMANS; LYMPHOMA, MANTLE-CELL; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 79960536012     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2011.06.001     Document Type: Article

References (11)

1. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993, 329:987-994.
2. Hoster E., Dreyling M., Klapper W., et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008, 111:558-565.
3. Hoster E., Hasford J., Hermine O., et al. Confirmation of the Mantle Cell Lymphoma International Prognostic Index (MIPI) in an independent prospective patient cohort. ASH Annual Meeting Abstracts 2009, 114:138.
4. van de Schans S.A., Janssen-Heijnen M.L., Nijziel M.R., et al. Validation, revision and extension of the Mantle Cell Lymphoma International Prognostic Index in a population-based setting. Haematologica 2010, 95:1503-1509.
5. Geisler C.H., Kolstad A., Laurell A., et al. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood 2010, 115:1530-1533.
6. Shah J.J., Fayad L., Romaguera J. Mantle Cell International Prognostic Index (MIPI) not prognostic after R-hyper-CVAD. Blood 2008, 112:2583.
7. Romaguera J.E., Fayad L.E., Feng L., et al. Ten-year follow-up after intense chemoimmunotherapy with rituximab-HyperCVAD alternating with rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 2010, 150:200-208.
8. Chiappella A., Puccini B., Ferrero S., et al. Retrospective analysis of 206 mantle cell lymphoma patients at diagnosis: Mantle Cell International Prognostic Index (MIPI) is a good predictor of death event in patients treated either with rituximab-chemotherapy or rituximab-high-dose-chemotherapy. ASH Annual Meeting Abstracts 2010, 116:1784.
9. Salek D., Vasova I., Pytlik R., et al. Mantle Cell Lymphoma International Prognostic Score is valid and confirmed in unselected cohort of patients treated in rituximab era. ASH Annual Meeting Abstracts 2008, 112:3745.
10. Eve H.E., Gambell J., Smith P., et al. The Simplified Mantle-Cell Lymphoma International Prognostic Index predicts overall survival but not progression-free survival in patients with mantle-cell lymphoma treated with flud.arabine and cyclophosphamide +/- rituximab: results of a randomized phase II trial. Leuk Lymphoma 2009, 50:1709-1711.
11. Chiappella A., Puccini B., Rossi M., et al. Mantle Cell International Prognostic Index (MIPI) is a strong predictor of the outcome of mantle cell lymphoma (MCL) in the rituximab (R) era. ASH Annual Meeting Abstracts 2009, 114:2928.